Search Results for “research” – Page 23 – media

New research uncovers how dietary fiber helps intestinal cells maintain gut health

UC Davis Health researchers have discovered how by-products of the digestion of dietary fiber by gut microbes act as the right fuel to help intestinal cells maintain gut health.
- Source: news-medical.net
- 451
- August 11, 2017
gut Researches
Researchers develop new ultrafast antibiotic resistance test

Researchers at Uppsala University have developed a new method for very rapidly determining whether infection-causing bacteria are resistant or susceptible to antibiotics.
- Source: news-medical.net
- 701
- August 9, 2017
antibiotic resistance bacteria Researches
Researchers demonstrate potential of new PET tracer for imaging prostate cancer

In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the University of Michigan demonstrate the potential of a new PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), for imaging prostate cancer, and set the stage for its possible use in monitoring other cancers.
- Source: news-medical.net
- 541
- August 8, 2017
cancer Company Insight PET prostate tracer
US researchers say blood test can detect Alzheimer’s early

Researchers at Washington University School of Medicine in St Louis, US, have carried out a study to identify a rapid and inexpensive test for Alzheimer’s disease.
- Source: Medical devices
- 448
- July 21, 2017
Alzheimer's Researches
Sanofi, Ablynx sign $2.7bn research, licensing pact

Sanofi has signed a research pact and licensing deal with Ablynx that could bring as much as $2.7 billion euros to the Belgian biotech’s coffers if all targets are met.
- Source: pharmatimes
- 500
- July 21, 2017
Company Insight Market Views Sanofi Ablynx
Hand in hand with Merck and acquire shares from Zhongsheng Pharmaceutical! Lixin Pharmaceutical has become a dark horse in the development of new drugs, with a total pipeline BD transaction volume exceeding 28 billion yuan

November 21, 2024 07:30 Author: Du Sumin Source: Time Weekly 1 In just one week, two business development (BD) transactions with a total transaction amount exceeding 20 billion yuan have made innovative pharmaceutical company Lixin Pharmaceutical the focus of attention in the industry. On November 20th, China Biopharmaceutical (01177.HK, hereinafter referred to as “Zhongsheng Pharmaceutical”) announced that it had signed an equity investment and strategic cooperation agreement with Lixin Pharmaceutical. Accordingly, with an investment of 142 million yuan, Sinopharm will acquire 4.91% of the equity of Lixin Pharmaceutical. At the same time, it will reach strategic cooperation in Chinese Mainland on the LM-108 monoclonal antibody targeting CCR8 independently developed by Lixin Pharmaceutical, and has the right to choose multiple double antibody or ADC innovative drugs in the research pipeline of Lixin Pharmaceutical for cooperation. The specific terms will be otherwise agreed. This is the second BD transaction conducted by Lixin ...
- Source: drugdu
- 32
- November 22, 2024
Junshi Biotechnology introduces two cancer dual target fusion protein drugs

On the evening of November 19th, Junshi Biotechnology announced that it had signed a license agreement with the licensor. The licensor granted Junshi Biological the exclusive license right and sub license right to develop, manufacture, use, import, export, sell and commercialize the two double target fusion proteins in the Greater China region (including the Chinese Mainland, Hong Kong, Macao and Taiwan regions). At the same time, Junshi Biological and the licensor enjoy all the rights and interests to develop, manufacture, use, import, export, sell and commercialize one of the licensed products in the world in accordance with the equity ratio of 50%: 50%. After the signing of the license agreement, Junshi Biotechnology will make a down payment of 1.5 million US dollars (approximately 10.86 million RMB) to the licensor. Junshi Biotechnology will pay a milestone payment of no more than RMB 740 million to the licensor based on the progress ...
- Source: drugdu
- 29
- November 22, 2024
China Biopharmaceuticals announces signing equity investment and strategic cooperation agreement with Lixin Pharmaceutical

China Biopharmaceutical invested in New Pharmaceuticals with self raised funds, and reached strategic cooperation on LM-108 and many potential innovative bispecific antibodies or antibody conjugated drugs (ADC) in Chinese Mainland. According to the announcement, this agreement includes equity investment and strategic cooperation. In terms of equity investment, Lixin Pharmaceutical announced on October 18, 2024, the completion of a RMB 300 million C1 round of financing, raising funds to accelerate the development of clinical pipeline drugs and the construction of innovation platforms. According to the capital increase subscription agreement, China Biopharmaceutical, as the lead investor in this round of financing, paid RMB 142 million to Lixin Pharmaceutical and acquired 4.91% equity of Lixin Pharmaceutical after this transaction. In terms of strategic cooperation: China Biopharmaceutical and Lixin Pharmaceutical reached a strategic cooperation agreement on LM-108 in Chinese Mainland. In addition, Chinese biopharmaceuticals have the right to choose multiple bispecific antibodies or ADC ...
- Source: drugdu
- 28
- November 22, 2024
Regeneron’s midlife crisis

Regeneron is a role model for the biotech community. No biotech company wants to be Regeneron. “Becoming China’s Regeneron” is the slogan of many domestic biotechs. However, such a Regeneron cannot escape its midlife crisis. The attack of opponents, the victory of Eylea generic drugs, and the successive blows of dual-antibodies have put Regeneron in an extremely delicate stage. On the one hand, with two blockbuster drugs, Regeneron has completed the transformation from biotech to big pharma. In the first half of the year, its stock price continued to rise, successfully breaking through the $100 billion threshold, and its market value reached $133.2 billion. On the other hand, although the market believes in Regeneron’s R&D and platform technology capabilities, how can a new billion-dollar blockbuster drug be so easy? And Regeneron’s highly anticipated oncology business is not as glamorous as autoimmunity and ophthalmology, and its progress is also lackluster. So ...
- Source: drugdu
- 29
- November 22, 2024
Over 5.7 billion! China’s dual antibody ADC goes global+1

On November 18th, VelaVigo Cayman Limited announced a global strategic partnership agreement with Avenzo Therapeutics, Inc. (Avenzo). According to the agreement, Orange Sail Pharmaceuticals will grant Avenzo the development, production, and commercialization of Nectin4/TROP2 bispecific antibody conjugates worldwide (excluding Greater China), while retaining relevant rights in Greater China. Both parties will jointly promote the development and clinical application of the project on a global scale. The project plans to submit an IND to the US Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA) of China by 2025. According to the terms of the agreement, Orange Sail Pharmaceuticals will receive a down payment of up to $50 million and recent milestone payments. After achieving key milestones in development, regulatory approval, and sales, the company is expected to receive up to $750 million in follow-up milestone payments and tiered royalty payments based on sales in the Avenzo region. ...
- Source: drugdu
- 43
- November 21, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.